Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

What happened

Mirum Pharmaceuticals reported third-quarter 2026 global net product sales of $185.7 million, including $133.4 million for LIVMARLI and $52.3 million for Bile Acid Medicines. It raised its full-year net product sales guidance to $715 million to $720 million and cited ATEBRIOZ approval and launch and positive Phase 3 results.

Confirmed

Global impact / market context

Higher product sales and raised guidance point to stronger expected revenue from Mirum’s commercial medicines. If sales growth continues, more revenue could support spending on development and launches; conversely, weaker sales could make it harder to fund these activities without reducing cash available or seeking financing.

Analyst inference

The article describes growth in both reported product categories: LIVMARLI sales rose 45% year over year and Bile Acid Medicines sales rose 28%. Investors may weigh that commercial growth against the time and uncertainty involved in turning positive late-stage trial results into approved, marketed treatments.

Analyst inference

What to watch

1. Check subsequent quarterly reports for whether global product sales and sales of LIVMARLI and Bile Acid Medicines continue growing at a pace consistent with the raised full-year guidance. Analyst inference
2. Watch whether the reported ATEBRIOZ approval and launch translate into sales, and whether the company announces the five potential approvals and label expansions it described. Analyst inference
3. Follow the additional brelovitug data and regulatory decisions on potential new uses, since positive trial results alone do not establish approval or future revenue. Analyst inference

Evidence

• Original source link unavailable